Almirall, Cipher deal

Almirall granted Cipher Canadian commercialization rights to Vaniqa eflornithine and Actikerall fluorouracil/salicylic acid. Almirall will receive an upfront payment of C$450,000 ($360,495) and is eligible for undisclosed sales milestones. Almirall will be responsible for manufacturing and supplying the drugs to Cipher. The partners declined to disclose further details. ...